You are viewing: Spain AI in Life Science Market analysis
Part of: AI in Life Science Market (Global)

The Spain AI in Life Science Market was valued at $482.6 Million in 2026 and projected to reach to $1543.8 Million by 2031, representing a compound annual growth rate of 26.2%. Spain's AI in Life Science market is positioned for substantial growth through 2031, driven by increased investment in healthcare innovation and digital transformation initiatives across the country's pharmaceutical and biotech sectors.

Spain AI in Life Science Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Spain AI in Life Science Market Trends and Insights

  • This represents a compound annual growth rate of 26.2%, reflecting Spain's increasing adoption of artificial intelligence across pharmaceutical research, clinical diagnostics, and personalized medicine initiatives.
  • Spain's healthcare sector is leveraging AI technologies to accelerate drug discovery, optimize clinical workflows, and enhance patient outcomes, positioning the country as a key growth hub within the European life sciences ecosystem. The forecast period from 2026 to 2031 will witness significant investment in Spain's AI infrastructure, driven by government support for digital health transformation and private sector innovation.
  • Spain's life science companies are integrating machine learning algorithms, predictive analytics, and natural language processing to streamline operations and reduce time-to-market for new therapeutics.
  • This growth trajectory underscores Spain's commitment to becoming a competitive player in the global AI-driven life sciences landscape..

Key Market Statistics

  • CAGR (2026-2031) 26.2% CAGR
  • Market Size, 2026 ~USD 482.6 Million
  • Forecast, 2031 ~USD 1543.8 Million
  • Country Spain

Spain AI in Life Science Market Overview

Market Valuation Growth :

Spain's AI in Life Science market is valued at $482.6 million in 2026 and is projected to expand to $1,543.8 million by 2031, representing a 220% increase over the five-year forecast period.

Strong CAGR Performance :

Spain's market is growing at a compound annual growth rate of 26.2%, slightly below the global average of 26.3%, indicating competitive positioning within the international AI life science landscape.

Key Application Areas :

Spain's AI adoption is concentrated in pharmaceutical research, clinical diagnostics, and personalized medicine initiatives, driven by the country's advanced healthcare infrastructure and research institutions.

Healthcare Sector Leverage :

Spain's robust healthcare system is actively integrating AI technologies to enhance drug discovery, improve diagnostic accuracy, and develop tailored treatment protocols for patient populations.

Spain AI in Life Science Market Dynamics

  • Spanish research institutions and healthcare providers are increasingly adopting AI-powered solutions to accelerate drug development cycles and improve clinical outcomes.
  • Government support for digital health infrastructure and collaboration between academic centers and private enterprises are expected to further accelerate market expansion.
  • The convergence of Spain's strong scientific talent pool with growing venture capital interest in healthtech creates a favorable environment for sustained market development and technological advancement in personalized medicine and diagnostics..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • Spain's AI in Life Science market will grow from $482.6M (2026) to $1,543.8M (2031) at a 26.2% CAGR.
    • Spain is leveraging AI for drug discovery, clinical diagnostics, and personalized medicine applications.
    • Government digital health initiatives and private sector investment are driving Spain's market expansion.
    • Spain is positioning itself as a competitive European hub for AI-enabled life sciences innovation.

    AI in Life Science Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment NATURAL LANGUAGE PROCESSING (Tool)
    Forecast Period 2026–2031
    Growth Rate CAGR of 26.3% from 2026 to 2031
    Largest Segment CLINICAL APPLICATIONS (Application)
    Market Size Base Year (Billions) ~USD 21.58 (2026)
    Revenue Forecast (Billions) ~USD 69.34 (2031)
    Segments Covered Tool, Type, Application, Component, Deployment, End User, Offering, Deployment Mode

    Spain AI in Life Science Market Report Segmentation

    8 segment dimensions are covered across the global market.

    By Tool

    • Computer Vision
    • Context-Aware Processing And Computing
    • Image Analysis (Including Optical Character Recognition)
    • Machine Learning
    • Natural Language Processing

    By Type

    • Clinical Trials
    • Convolutional Neural Networks
    • Data Analytics & Reporting
    • Deep Learning
    • Drug Discovery
    • Generative Adversarial Networks
    • Graph Neural Networks
    • Manufacturing & Quality Assurance
    • Medical Imaging & Diagnostics
    • Other Clinical Applications
    • Other Machine Learning Technologies
    • Precision Medicine
    • R&D Support
    • Recurrent Neural Networks
    • Regulatory Affairs
    • Reinforcement Learning
    • Supervised Learning
    • Unsupervised Learning

    By Application

    • Clinical Applications
    • Non-Clinical Applications

    By Component

    • Service
    • Services
    • Software

    By Deployment

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    By End User

    • Academic & Government Laboratories
    • Biotechnology Companies
    • Cro & Cdmo
    • Diagnostic Companies
    • Other End Users
    • Pharmaceutical Companies

    By Offering

    • AI Technology
    • End-To-End Solutions
    • Niche/Point Solutions
    • Services

    By Deployment Mode

    • Cloud-Based Solutions
    • Hybrid Solutions
    • On-Premise Solutions

    SPAIN: AI IN LIFE SCIENCE MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & GOVERNMENT LABORATORIES23.929.637.247.259.174.894116.725.7
    BIOTECHNOLOGY COMPANIES65.781.7103.7132.3166.8212.3268.5335.826.5
    CRO & CDMO54.667.585.2108.1135.6171.6215.9268.525.8
    DIAGNOSTIC COMPANIES27.133.642.554.268.286.6109.3136.426.2
    OTHER END USERS12.915.92025.331.639.950.162.125.5
    PHARMACEUTICAL COMPANIES123.2153.1194247.1311.2395.6499.8624.226.3
    TOTAL307.4381.4482.6614.1772.5980.81237.51543.826.2

    Target Audience

    • Pharmaceutical Companies : Spanish and international pharma firms need market intelligence to assess AI investment opportunities, identify acquisition targets, and develop R&D strategies aligned with Spain's growing AI adoption in drug discovery.
    • Healthcare Technology Investors : Venture capital and private equity firms focused on healthtech require Spain-specific market data to evaluate investment potential, identify emerging startups, and understand market dynamics in the Spanish AI life science sector.
    • Biotech & Life Science Startups : Spanish and European biotech companies need detailed market sizing and growth forecasts to validate business models, secure funding, and plan expansion strategies within Spain's AI-driven life science ecosystem.
    • Healthcare Policy & Government Bodies : Spanish health authorities and policy makers require market analysis to inform digital health initiatives, allocate research funding, and develop regulatory frameworks supporting AI adoption in clinical and pharmaceutical settings.
    • Clinical Research Organizations : CROs and academic medical centers in Spain need market insights to understand AI integration opportunities, benchmark against peers, and develop partnerships with technology providers in the evolving Spanish healthcare landscape.

    Key Companies in the Spain AI in Life Science Market

    CompanyHQOwnershipStrongest segments
    NVIDIA CORPORATIONUnited StatesPublic CompanyData Center AI & Accelerated Computing (Compute & Networking),Gaming GPUs (GeForce),Professional Visualization (RTX/Quadro),
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    TEMPUS AI, INC.United StatesPublic CompanyOncology NGS diagnostics (xT, xR, large-panel solid and hematologic assays),Other clinical diagnostics (PCR, pathology, germline, pharmacogenomics nP),Life sciences data, AI platforms, and software (Lens, Insights, Next, Algos, Organoids, Trials),
    RECURSIONUnited StatesPublic CompanyPlatform and collaboration revenue,Internal pipeline and other revenue,
    DASSAULT SYSTèMES SEFrancePublic Company3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA),
    SCHRÖDINGER, INC.United StatesPublic CompanySoftware,Drug Discovery – Collaborations and Milestones,Drug Discovery – Internal Programs and Other,
    MICROSOFT CORPORATIONUnited StatesPublic CompanyProductivity and Business Processes,Intelligent Cloud,Personal Computing,
    BENEVOLENTAI LIMITEDUnited KingdomPrivate CompanyAI R&D decision-support platform (licenses and subscriptions),Collaborative discovery projects and services,Data and ontology integration / customization,

    NVIDIA CORPORATION

    NVIDIA Corporation is a U.S. public company founded in 1993 that employs 42,000 people. The company designs and manufactures graphics processing units and system-on-chip units for gaming, professional visualization, data centers, and artificial intelligence applications.

    ILLUMINA, INC.

    Illumina, Inc. is a U.S. public company founded in 1998 with 8,625 employees. The company develops and manufactures sequencing and array-based solutions for genetic analysis and molecular diagnostics.

    TEMPUS AI, INC.

    Tempus AI, Inc. is a U.S. public company founded in 2015 with 3,800 employees. The company applies artificial intelligence and machine learning to healthcare data to improve clinical decision-making and patient outcomes.

    RECURSION

    Recursion is a U.S. public company founded in 2013 with 600 employees. The company uses artificial intelligence and high-throughput biology to discover and develop novel therapeutics.

    DASSAULT SYSTèMES SE

    Dassault Systèmes SE is a French public company founded in 1981 with 25,000 employees. The company develops and markets 3D design, digital mock-up, and product lifecycle management software solutions.

    SCHRÖDINGER, INC.

    Schrödinger, Inc. is a U.S. public company founded in 1990 with 850 employees. The company provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.

    MICROSOFT CORPORATION

    Microsoft Corporation is a U.S. public company founded in 1975 with 228,000 employees. The company develops, manufactures, and sells computer software, consumer electronics, personal computers, and cloud computing services.

    BENEVOLENTAI LIMITED

    BenevolentAI Limited is a United Kingdom private company founded in 2013 with 173 employees. The company uses artificial intelligence to accelerate drug discovery and development for various therapeutic areas.

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise valuation data for Spain's AI in Life Science market with verified CAGR of 26.2%, enabling accurate financial forecasting and investment decision-making for the 2026-2031 period.
    • Competitive Positioning Intelligence : Benchmark Spain's market performance against global trends (26.3% global CAGR) to identify competitive advantages and market opportunities specific to the Spanish healthcare and pharmaceutical landscape.
    • Sector-Specific Application Insights : Access detailed analysis of AI implementation across Spain's pharmaceutical research, clinical diagnostics, and personalized medicine sectors to identify high-potential investment and partnership opportunities.
    • Strategic Market Entry Planning : Leverage Spain-specific market data to develop targeted go-to-market strategies, identify key stakeholders, and understand regulatory requirements for AI life science solutions in the Spanish market.
    • Risk Assessment & Opportunity Mapping : Evaluate market dynamics, growth drivers, and potential headwinds specific to Spain's healthcare sector to inform risk mitigation strategies and long-term business planning in the region.

    Frequently asked questions

    What is the current size of Spain's AI in Life Science market?

    Spain's AI in Life Science market is valued at $482.6 million in 2026.

    What is the projected market size for Spain by 2031?

    Spain's AI in Life Science market is projected to reach $1,543.8 million by 2031.

    What is the CAGR for Spain's AI in Life Science market?

    Spain's AI in Life Science market is expected to grow at a compound annual growth rate of 26.2% from 2026 to 2031.

    Which applications of AI are driving growth in Spain's life sciences sector?

    Spain's life sciences sector is adopting AI for drug discovery, clinical diagnostics, predictive analytics, and personalized medicine applications.

    What factors are supporting Spain's AI in Life Science market expansion?

    Government support for digital health transformation, private sector innovation, and integration of machine learning and natural language processing technologies are key growth drivers in Spain.

    RESEARCH METHODOLOGY

    The study involved five major activities to estimate the current size of the AI in life science market. Exhaustive secondary research was conducted to collect information on the market and its subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.  

    Secondary Research

    In the secondary research process, various secondary sources, including annual reports, press releases and investor presentations from companies, white papers, certified publications, articles by recognized authors, gold- and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were consulted to identify and collect information for the study of the AI in the life science market. These sources were also used to obtain important information about the top players, market classification and segmentation by industry trends down to the bottom-most level, geographic markets, and key developments related to the market. A database of key industry leaders was also prepared using secondary research.

    Primary Research

    Extensive primary research was conducted after obtaining basic information of the global AI in life science market through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital directors, hospital vice presidents, department heads, and critical care specialists) and the supply side (such as C- and D-level executives, technology experts, product managers, marketing and sales managers, among others) across five major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

    The following is a breakdown of the primary respondents:

    BREAKDOWN OF PRIMARY PARTICIPANTS:

    AI in Life Science Market Size, and Share

    Note 1: Others include sales managers, marketing managers, and product managers.
    Note 2: Tiers of companies are defined on the basis of their total revenues in 2025. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in life science market. These methods were also used extensively to estimate the size of various subsegments in the market.

    AI in Life Science Market : Top-Down and Bottom-Up Approach

    AI in Life Science Market Top Down and Bottom Up Approach

    Data Triangulation

    After determining the overall market size using market size estimation processes, the market was segmented into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for each market segment and subsegment, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides in the AI in life science market. 

    Market Definition

    AI in life sciences refers to the application of artificial intelligence technologies to analyze complex biological, clinical, and healthcare data to improve research, development, and patient outcomes. It uses advanced algorithms and computational models to support areas such as drug discovery, disease diagnosis, clinical trials, and precision medicine, enabling faster insights and more efficient decision-making across the life sciences ecosystem.

    Key Stakeholders

    • Pharmaceutical & Biotechnology Companies
    • Contract Research Organizations (CROs) & Clinical Trial Partners
    • Healthcare Providers (Hospitals, Clinics, Telehealth Providers)
    • Digital Health & AI Solution Providers
    • Cloud & Data Infrastructure Providers
    • Data Analytics & Software Platform Providers
    • Payers & Insurance Companies
    • Regulatory & Compliance Bodies (e.g., FDA, EMA)
    • Academic & Research Institutions
    • Patients & End Users
    • Technology Integrators & Consulting Firms

    Report Objectives

    • To define, describe, and forecast the global AI in life science market based on type, therapeutic area, application, end user, and region
    • To provide detailed information regarding the major factors (such as drivers, restraints, opportunities, and challenges) influencing market growth
    • To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall AI in life science market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To strategically analyze the market structure profile of the key players of the AI in life science market and comprehensively analyze their core competencies
    • To forecast the size of the market segments with respect to five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
    • To analyze competitive developments such as product launches and enhancements, investments, partnerships, collaborations, acquisitions, expansions, product approval, and alliances in the AI in life science market during the forecast period

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Product Analysis

    • Product matrix, which gives a detailed comparison of the product portfolios of each company.

    Regional Analysis

    • Further breakdown of the Latin America, Europe, and Middle East & Africa AI in life science market into specific countries

    Get the Full AI in Life Science Market Report

    Full forecast, segment splits, and company analysis for all AI in Life Science Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status